C5aR1 Modulators Targeting Complement System Infection Risks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating disorders related to the C5a-C5aR1 axis are limited by the inability to effectively target C5a receptors without affecting other components of the complement system, leading to incomplete therapeutic effects and potential risks of infection complications.
Innovation Solution
Development of novel C5aR1 modulators with high binding affinity to the C5a receptor, which directly target and block C5a-mediated physiological effects, thereby avoiding the drawbacks of targeting C5 or C3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If upstream complement molecules (C5 or C3) are targeted for treatment, then therapeutic effects are achieved, but the risk of infection complications increases and other complement system components are affected
Solution Approach 1:
The patent segments the complement system treatment approach by developing compounds that specifically target only the C5a-C5aR1 axis rather than upstream molecules like C3 or C5. This segmentation allows selective inhibition of the C5a receptor while preserving other complement pathways, thereby maintaining therapeutic effects while reducing the risk of infection complications associated with broader complement system suppression
Solution Approach 2:
The patent applies local quality by creating highly selective C5aR1 modulators that act locally at the specific receptor site rather than systemically affecting upstream complement molecules. The compounds of formula (I) and its salts are designed to bind specifically to C5aR1 with high affinity, providing localized therapeutic action at the receptor level while sparing other complement system components from inhibition
2Reliability
If C5aR1 is directly targeted with high binding affinity, then blocking activity for C5a-mediated effects is improved, but compound structure complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters of the compounds of formula (I), including variations in substituents R1-R6, R8-R9, aryl and heteroaryl groups, and their positions. These parameter changes are optimized to achieve high binding affinity and blocking activity at the C5aR1 receptor while managing structural complexity through deliberate molecular design
Data Source
AI summary
The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.